Overview

Dexmedetomidine to Prevent Hepatic Ischemia-reperfusion Injury-induced Glycocalyx Degradation and Early Allograft Dysfunction in Liver Transplantation

Status:
Not yet recruiting

Trial end date:
2024-12-15

Target enrollment:

Participant gender:

Summary

the aim of the study is to approve the hypothesis that dexmedetomidine can protect against glycocalyx degradation induced by hepatic ischemia-reperfusion injury and hence can reduce the subsequent complications as early allograft dysfunction, other organ dysfunction and hemodynamic instability

Phase:

Phase 4

Details

Lead Sponsor:

Assiut University

Treatments:

Dexmedetomidine